Specialty Injectable Generics Market Outlook 2032
The global specialty injectable generics market size was USD 20.9 Million in 2023 and is projected to reach USD 44.2 Million by 2032, expanding at a CAGR of 8.7% during 2024–2032. The market growth is attributed to the increasing demand for affordable healthcare solutions and advancements in pharmaceutical technology.
Increasing demand for cost-effective alternatives in the healthcare sector is resulting in the high adoption of specialty injectable generics, thereby boosting the market. Healthcare providers, pharmaceutical companies, and patients are increasingly recognizing the benefits of these medications, leading to a growing consumer base. Furthermore, the increasing adoption of generic drugs, due to government initiatives to lower healthcare costs, is also expected to fuel the market in the coming years.
-
According to the report published on August 29, 2023, the global sales of generic prescription drugs generated USD 74 billion in 2020. It is expected that by 2026, the sales of prescribed generics across the globe to reach nearly USD 100 billion.
Impact of Artificial Intelligence (AI) in the Specialty Injectable Generics Market
The use of artificial intelligence is likely to boost the specialty injectable generics market. AI-powered algorithms analyze large datasets to identify potential drug candidates with high success rates. Additionally, AI-driven predictive analytics optimize inventory management to ensure the timely availability of medications and minimize stockouts.
Specialty Injectable Generics Market Dynamics
Major Drivers
High prevalence of chronic diseases and increasing patient population is projected to fuel the market during the forecast period. Chronic diseases, including cancer, diabetes, autoimmune disorders, and cardiovascular diseases, create a growing need for effective and affordable treatment options such as specialty injectable generics. Moreover, the increasing emphasis on value-based healthcare and cost-containment strategies is further boosting the demand for specialty injectable generics.
Existing Restraints
Limited patient and physician acceptance of specialty injectable generics is expected to hinder the market in the coming years. Specialty injectable generics encounter resistance from patients and healthcare providers due to concerns about efficacy, safety, and interchangeability. Moreover, the reimbursement policies and formulary restrictions often favor brand-name drugs over generic alternatives, which further hampers the market.
Emerging Opportunities
Surging investment in research and development (R&D) for the development of specialty injectable generics is expected to create immense opportunities for the players competing in the market during the forecast period. Pharmaceutical companies focusing on the development of generic versions of complex biologics and specialty drugs to cater the growing demand for affordable treatment options. Furthermore, the high demand for biosimilars is expected to boost the market during the forecast period.
Scope of the Specialty Injectable Generics Market Report
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Specialty Injectable Generics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2023
|
|
Historic Data
|
2017 -2022
|
|
Forecast Period
|
2024–2032
|
|
Segmentation
|
Type (Drugs and Biologics), Application (Infectious Diseases, Oncology, Multiple Sclerosis, Hepatitis C, CNS, Cardiovascular, Autoimmune Disorders, and Others), and End-User (Retail Pharmacy, Specialty Pharmacy, and Hospital Pharmacy)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Baxter; Dr. Reddy’s Laboratories Ltd; Fresenius SE & Co. KGaA; Hikma Pharmaceuticals PLC; Novartis Pharmaceuticals Corporation; Par Pharmaceutical, Inc; Pfizer Inc; Sagent Pharmaceuticals; and Teva Pharmaceutical Industries Ltd.
|
Specialty Injectable Generics Market Segment Insights
Type Segment Analysis
Based on type, the specialty injectable generics market is divided into drugs and biologics. The biologies segment held a major share of the market in 2023, owing to their widespread use in the treatment of various chronic diseases such as cancer, autoimmune disorders, and infectious diseases. Moreover, the growing demand for targeted therapies further fuels the adoption of biologics for their high specificity and efficacy.
The drugs segment is expected to expand at a significant growth rate in the coming years, owing to the offer of cost-effective alternatives to biologics, particularly in therapeutic areas where small-molecule medications are effective. Additionally, the development of generic versions of brand-name drugs, including injectable formulations is boosting the segment.
Application Segment Analysis
On the basis of application, the global market is segregated into infectious diseases, oncology, multiple sclerosis, hepatitis C, CNS, cardiovascular, autoimmune disorders, and others. The oncology segment held a large market share in 2023, due to the increasing incidences of cancer globally. For instance, according to the report published by the American Cancer Society, around 1.9 million new cancer cases were diagnosed in 2022.
This trend led to a growing need for effective and affordable cancer treatments, including injectable medications. Moreover, the high cost of branded oncology drugs fuels the demand for cost-effective alternatives, such as generic injectables, which further boosts the market.
The autoimmune disorders segment is anticipated to expand at a substantial CAGR during the forecast period, owing to the demand for specialty injectable generics as effective autoimmune treatment options for these types of diseases. Additionally, the complexity of autoimmune diseases often requires long-term treatment with biological medications further propelling the utilization of cost-effective injectable generics for patients.
End-user Segment Analysis
Based on end-user, the specialty injectable generics market is segmented into retail pharmacy, specialty pharmacy, and hospital pharmacy. The specialty pharmacy segment is projected to register a robust growth rate during the assessment years, owing to the expansion of specialty pharmacy networks and the availability of mail-order and home-delivery services. Moreover, the increasing demand for specialized pharmacy services further boosts the segment during the projected period.
Regional Outlook
In terms of region, the global specialty injectable generics market is classified as Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa. North America held a major market share in 2023, due to the high level of healthcare expenditure, driving demand for specialty injectable generics. Moreover, the favorable regulatory policies and expedited approval pathways for generic drugs in countries, including the US further facilitate the market in this region.
The market in Asia Pacific is projected to grow at a significant pace in the years to come, owing to the growing demand for affordable specialty injectable generics among a large and rapidly expanding population. Moreover, the rising awareness about the benefits of generic medications is expected to fuel the market in this region.
Segments
The specialty injectable generics market has been segmented on the basis of
Type
Application
- Infectious Diseases
- Oncology
- Multiple Sclerosis
- Hepatitis C
- CNS
- Cardiovascular
- Autoimmune Disorders
- Others
End-user
- Retail Pharmacy
- Specialty Pharmacy
- Hospital Pharmacy
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global specialty injectable generics market are Baxter; Dr. Reddy’s Laboratories Ltd; Fresenius SE & Co. KGaA; Hikma Pharmaceuticals PLC; Novartis Pharmaceuticals Corporation; Par Pharmaceutical, Inc; Pfizer Inc; Sagent Pharmaceuticals; and Teva Pharmaceutical Industries Ltd
These companies use development strategies including mergers, acquisitions, partnerships, collaboration, and product launches to expand their consumer base globally.
-
On March 1, 2024, Mallinckrodt, a global pharmaceutical company, announced the FDA sanctioned its new drug application of a single-dose pre-filled injector of Acthar Gel, repository corticotropin injection. This development marks the advent of a modern delivery system tailored to patients grappling with a wide array of chronic and acute inflammatory and autoimmune conditions. Moreover, Acthar Gel contains a naturally complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides.
Request For Customization
Enquiry Before Buying
Speak With Analyst
